REGENXBIO Inc. RGNX
$8.91
+10.61%
at last close
Market Cap$531.74 million
P/E Ratio—
Div Yield—
Volume1.76M
52-Week Range
$5.46$16.19
Analyst Ratings
- Consensus
- Buy — 8 Buy · 2 Hold · 0 Sell (10 analysts)
- Avg. Price Target
- $23.70 (+166.0% upside)
Key Stats
- Today's Range
- $8.13 – $8.99
- 50-Day Range
- $6.58 – $15.88
- 52-Week Range
- $5.46 – $16.19
- Volume
- 1.76 million shs
- Average Volume
- 1.58 million shs
- Market Cap
- $531.74 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 7.41
- Price / Sales
- 3.05
Short Interest
- Short Interest
- 1.96%
- Days to Cover
- 5.34
Financials (TTM)
- Revenue
- $174.48 million
- Net Income
- $-196,432,000
- Net Margin
- -112.58%
- Return on Equity
- -273.72%
- Debt-to-Equity
- —
About REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
Related Stocks
Compare head-to-head: RGNX vs AMGN·RGNX vs MRNA·RGNX vs HALO·RGNX vs RGEN
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.